Guillain-Barre Syndrome Drugs Global Market Report 2024

Description

Guillain-Barre syndrome drugs are medications designed to address the symptoms and complications associated with Guillain-Barre syndrome (GBS), an autoimmune condition characterized by the immune system attacking the nervous system. These drugs primarily target modulating the activity of the peripheral immune system to slow down the disease's progression and alleviate its symptoms.

The primary classes of Guillain-Barre syndrome drugs include immunoglobulins (IVIG), corticosteroids, and plasma exchange. Intravenous immunoglobulin (IVIG) is a medication derived from pooled human blood plasma containing a high concentration of antibodies. It is used as a first-line treatment and in adjunctive or supportive therapy, finding widespread use in clinics, hospitals, and other medical settings.

The Guillain-Barre syndrome drugs market research report is one of a series of new reports from The Business Research Company that provides Guillain-Barre syndrome drugs market statistics, including Guillain-Barre syndrome drugs industry global market size, regional shares, competitors with a Guillain-Barre syndrome drugs market share, detailed Guillain-Barre syndrome drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Guillain-Barre syndrome drugs industry. This Guillain-Barre syndrome drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Guillain-Barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.08 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The historical growth can be credited to advancements in research and development, government initiatives and regulatory support, heightened emphasis on neurology and autoimmune disorders, greater attention to lowering healthcare expenditures, and an uptick in the need for hospital and clinic services.

The Guillain-Barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.59 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The forecasted growth can be linked to the rising incidence rate of Guillain-Barre Syndrome (GBS), heightened awareness and diagnosis rates, expanding elderly population, escalating importance of hospital and retail pharmacies, and increased demand for oral and injectable medications. Key trends in this period encompass the emergence of novel treatments, progress in diagnostic technologies, partnerships between pharmaceutical firms and research entities, advancements in gene therapy, and improvements in intravenous immunoglobulin therapy.

The expected surge in demand for personalized medicine is set to drive growth in the Guillain-Barre syndrome drugs market. Personalized medicine involves customizing medical treatments based on individual characteristics such as genetics or lifestyle to optimize effectiveness and minimize side effects. This demand is fueled by the potential for more efficient treatments, advancements in genomics, the increasing complexity of diseases, and regulatory backing. In Guillain-Barre syndrome (GBS), personalized medicine aims to tailor treatments according to individual patient profiles, improving therapeutic outcomes and reducing adverse effects. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, as reported by the US-based non-profit organization, Personalized Medicine Coalition. This trend underscores how the rising preference for personalized medicine is pushing growth in the Guillain-Barre syndrome drugs market.

Key players in the guillain-barre syndrome drugs market are innovating by developing products such as humanized monoclonal antibodies to maintain their market presence. Humanized monoclonal antibodies are lab-made antibodies that combine human antibodies with parts of mouse or rat monoclonal antibodies. They are explored as potential therapies due to their ability to target specific immune system components involved in GBS pathology. For example, in October 2023, Annexon Inc., a US-based biopharmaceutical company, announced that ANX005 received orphan drug designation from the European Medicines Agency (EMA) and the FDA for GBS treatment. ANX005, a humanized monoclonal antibody, works by inhibiting C1q to halt complement-mediated inflammation and neuronal damage in early-stage GBS. Annexon has completed target enrollment in a Phase 3 trial of ANX005 in GBS, with top-line data expected in the first half of 2024. ANX005 aims to mitigate inflammation and nerve damage by selectively blocking C1q activity in the nervous system, promoting rapid cessation of autoimmune damage and muscle strength recovery in GBS patients.

In April 2022, Grifols SA, a Spanish pharmaceutical company, acquired Biotest AG for $1.17 billion, aiming to expand and diversify its plasma supply. This strategic move also strengthens Grifols' presence and revenues in Europe, the Middle East, and Africa, while fostering collaboration between Grifols and Biotest to improve global access to plasma-derived therapies. Biotest AG, based in Germany, provides drugs for Guillain-Barre syndrome (GBS) treatment.

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc

North America was the largest region in the Guillain-Barre syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the guillain-barre syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Guillain-Barre syndrome drugs market consists of sales of monoclonal antibodies, cell therapies, and recombinant enzymes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Guillain-Barre Syndrome Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on guillain-barre syndrome drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for guillain-barre syndrome drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The guillain-barre syndrome drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Immunoglobulins (IVIG); Corticosteroids; Plasma Exchange
2) By Treatment Type: First-Line Treatment; Adjunctive Or Supportive Treatment
3) By Application: Clinic; Hospital; Other Applications
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r18147

1. Executive Summary

2. Guillain-Barre Syndrome Drugs Market Characteristics

3. Guillain-Barre Syndrome Drugs Market Trends And Strategies

4. Guillain-Barre Syndrome Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Guillain-Barre Syndrome Drugs Market Size and Growth

5.1. Global Guillain-Barre Syndrome Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Guillain-Barre Syndrome Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Guillain-Barre Syndrome Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Guillain-Barre Syndrome Drugs Market Segmentation

6.1. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Immunoglobulins (IVIG)
Corticosteroids
Plasma Exchange
6.2. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
First-Line Treatment
Adjunctive Or Supportive Treatment
6.3. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Clinic
Hospital
Other Applications

7. Guillain-Barre Syndrome Drugs Market Regional And Country Analysis

7.1. Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Guillain-Barre Syndrome Drugs Market

8.1. Asia-Pacific Guillain-Barre Syndrome Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Guillain-Barre Syndrome Drugs Market

9.1. China Guillain-Barre Syndrome Drugs Market Overview
9.2. China Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Guillain-Barre Syndrome Drugs Market

10.1. India Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Guillain-Barre Syndrome Drugs Market

11.1. Japan Guillain-Barre Syndrome Drugs Market Overview
11.2. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Guillain-Barre Syndrome Drugs Market

12.1. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Guillain-Barre Syndrome Drugs Market

13.1. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Guillain-Barre Syndrome Drugs Market

14.1. South Korea Guillain-Barre Syndrome Drugs Market Overview
14.2. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Guillain-Barre Syndrome Drugs Market

15.1. Western Europe Guillain-Barre Syndrome Drugs Market Overview
15.2. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Guillain-Barre Syndrome Drugs Market

16.1. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Guillain-Barre Syndrome Drugs Market

17.1. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Guillain-Barre Syndrome Drugs Market

18.1. France Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Guillain-Barre Syndrome Drugs Market

19.1. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Guillain-Barre Syndrome Drugs Market

20.1. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Guillain-Barre Syndrome Drugs Market

21.1. Eastern Europe Guillain-Barre Syndrome Drugs Market Overview
21.2. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Guillain-Barre Syndrome Drugs Market

22.1. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Guillain-Barre Syndrome Drugs Market

23.1. North America Guillain-Barre Syndrome Drugs Market Overview
23.2. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Guillain-Barre Syndrome Drugs Market

24.1. USA Guillain-Barre Syndrome Drugs Market Overview
24.2. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Guillain-Barre Syndrome Drugs Market

25.1. Canada Guillain-Barre Syndrome Drugs Market Overview
25.2. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Guillain-Barre Syndrome Drugs Market

26.1. South America Guillain-Barre Syndrome Drugs Market Overview
26.2. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Guillain-Barre Syndrome Drugs Market

27.1. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Guillain-Barre Syndrome Drugs Market

28.1. Middle East Guillain-Barre Syndrome Drugs Market Overview
28.2. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Guillain-Barre Syndrome Drugs Market

29.1. Africa Guillain-Barre Syndrome Drugs Market Overview
29.2. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Guillain-Barre Syndrome Drugs Market Competitive Landscape And Company Profiles

30.1. Guillain-Barre Syndrome Drugs Market Competitive Landscape
30.2. Guillain-Barre Syndrome Drugs Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck & Co. Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Takeda Pharmaceutical Company Limited
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Guillain-Barre Syndrome Drugs Market Other Major And Innovative Companies

31.1. Biogen Inc.
31.2. Chugai Pharmaceutical Co. Ltd.
31.3. Grifols SA
31.4. Octapharma AG
31.5. Cadila Healthcare Limited
31.6. Argenx SE
31.7. Alnylam Pharmaceuticals Inc.
31.8. Biotest AG
31.9. CSL Behring LLC
31.10. Kedrion Biopharma Inc.
31.11. Cellenkos Inc.
31.12. Annexon Inc.
31.13. Hansa Medical AB
31.14. Akari Therapeutics Plc
31.15. Alexion Pharmaceuticals Inc.

32. Global Guillain-Barre Syndrome Drugs Market Competitive Benchmarking

33. Global Guillain-Barre Syndrome Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Guillain-Barre Syndrome Drugs Market

35. Guillain-Barre Syndrome Drugs Market Future Outlook and Potential Analysis

35.1 Guillain-Barre Syndrome Drugs Market In 2028 - Countries Offering Most New Opportunities
35.2 Guillain-Barre Syndrome Drugs Market In 2028 - Segments Offering Most New Opportunities
35.3 Guillain-Barre Syndrome Drugs Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer